You are here
Consultations
We consult on proposed changes to the way we regulate medicines, medical devices and biologicals. Additional consultations about changes to the Poisons Standard can be found in the Scheduling decisions (interim) section of our publications hub.
Filter results
You can narrow down the results using the filters
Topic
- Scheduling (national classification system) (68)
- Medical devices (62)
- Therapeutic goods regulation (13)
- Over the counter medicine (12)
- Prescription medicines (10)
- Complementary medicines (8)
- Medicines (8)
- Advisory bodies and committees (7)
- Legislation (6)
- Manufacturing (5)
- Biologicals (4)
- Labelling and packaging (4)
- Advertising (3)
- Listed medicines (3)
- Non-prescription medicines (3)
- Fees and payments (2)
- Sunscreens (2)
- Australian Register of Therapeutic Goods (ARTG) (1)
- Clinical trials (1)
- Import and export (1)
- In Vitro Diagnostic medical devices (IVDs) (1)
- Medical devices safety (1)
- Medicinal cannabis hub (1)
- Medicines safety (1)
- Nicotine vaping products hub (1)
- Other therapeutic goods (1)
- Safety (1)
- Unique Device Identification (UDI) Hub (1)
More on consultations
Find more scheduling consultations on the Poisons Standard in our Interim decisions.
Read the details of recent consultations, submissions and decisions at the TGA Consultation hub.
Trove at the National Library of Australia has information on archived TGA consultations and reviews.
Search
212 result(s) found, displaying 1 to 25
- Closed onConsultationConsultation: Clarification and updates to the regulation of sunscreensThe TGA is seeking feedback on proposed clarification and updates to the regulation of sunscreens. Closing date: 31 May 2023
- Closed onConsultationConsultation: Proposed amendments to the Poisons Standard – ACMS and Joint ACMS-ACCS meetings, June 2023Proposed amendments to the Poisons Standard. Closing date: 17 May 2023
- Closed onConsultationConsultation: Allied health professionals point-of-care manufacturing surveyThe TGA is conducting a public consultation to provide interested stakeholders with an opportunity to comment on regulatory pathways for medical devices manufactured at the point-of-care. Closing date: 7 May 2023
- Closed onConsultationConsultation: Dental and oral health professionals point-of-care manufacturing surveyThe TGA is conducting a public consultation to provide interested stakeholders with an opportunity to comment on regulatory pathways for medical devices manufactured at the point-of-care. Closing date: 7 May 2023
- Closed onConsultationConsultation: Hospital and healthcare facility surveyThe TGA is conducting a public consultation to provide interested stakeholders with an opportunity to comment on regulatory pathways for medical devices manufactured at the point-of-care. Closing date: 7 May 2023
- Closed onConsultationConsultation: Medical device manufacturing hubs at the point-of-care surveyThe TGA is conducting a public consultation to provide interested stakeholders with an opportunity to comment on regulatory pathways for medical devices manufactured at the point-of-care. Closing date: 7 May 2023
- Closed onConsultationConsultation: Repurposing of medicinesConsultation seeking feedback on the repurposing of medicines to inform the development of options for Government consideration closed 1 April 2022
- Closed onConsultationConsultation: TGA Fees and Charges Proposal 2023-24The TGA is conducting a public consultation to provide interested stakeholders with an opportunity to comment on options for the TGA's proposed fees and charges for the 2023-24 financial year. Closing date: 20 March 2023
- Closed onConsultationConsultation: Seeking feedback on improvements to the recalls processThe TGA is seeking feedback on improvements to the therapeutic goods recalls process. Closing 13 March 2023.
- Closed onConsultationPublic consultation on interim decisions to amend the Poisons Standard - ACMS #40 NOVEMBER 2022 (paracetamol)This consultation is for the interim decision in relation to paracetamol which was discussed at the November 2022 meeting of the Advisory Committee on Medicines Scheduling (ACMS).
- Closed onConsultationPublic consultation on interim decisions to amend the Poisons Standard - ACMS, ACCS & Joint ACMS-ACCS, NOVEMBER 2022This consultation is for interim decisions made in relation to the other substances that were discussed at the November 2022 meetings of the Advisory Committee on Medicines Scheduling (ACMS) and the Advisory Committee on Chemicals Scheduling (ACCS).
- Closed onConsultationConsultation: Proposed amendments to the Poisons Standard - ACMS, ACCS and joint ACMS-ACCS meetings, March 2023Proposed amendments to the Poisons Standard. Closing date: 3 February 2023
- Closed onConsultationConsultation: Proposed reforms to the regulation of nicotine vaping productsThe TGA is seeking public comment on potential reforms to the regulation of nicotine vaping products (NVPs) in Australia.
- Closed onConsultationConsultation: 2022-2023 Proposed changes to the Permissible Ingredients Determination - Low-negligible riskClosed: 15 September 2022. Consultation results are now available on the TGA Consultation Hub
- Closed onConsultationConsultation: International harmonisation of ingredient names (IHIN) – Dual labelling transition to sole medicine ingredient namesThe TGA is seeking views on ingredient names that must be displayed as both the old and new ingredient name on medicine labels.
- Closed onConsultationPublic consultation on interim decisions to amend the Poisons Standard - ACMS/ACCS/Joint ACMS-ACCS JUNE INTERIM DECISIONS 2022This consultation is for interim decisions made in relation to applications and delegate initiated proposals to amend the Poisons Standard, following advice sought at the June 2022 meetings of the Advisory Committee on Medicines Scheduling (ACMS) and the Advisory Committee on Chemicals Scheduling (ACCS).
- Closed onConsultationPublic consultation on interim decisions to amend the Poisons Standard - JUNE ACMS INTERIM DECISIONS FOR PSILOCYBINE AND MDMA 2022This consultation is for interim decisions made in relation to Psilocybine and MDMA proposals to amend the Poisons Standard, following advice sought at the June 2022 meetings of the Advisory Committee on Medicines Scheduling (ACMS).
- Closed onConsultationConsultation: Draft Guidance: Boundary and Combination products - medicines, medical devices and biologicalsThe TGA is seeking feedback on the draft guidance ‘Boundary and combination products - medicines, medical devices, and biologicals’.
- Closed onConsultationConsultation: Adoption of International Scientific Guidelines in Australia - closed November 2022The TGA is seeking feedback on whether certain international scientific guidelines should be adopted.
- Closed onConsultationConsultation: Regulatory options to potentially allow references to the TGA in therapeutic goods advertisingThe TGA is considering regulatory options to allow advertisers, including product sponsors, to make references to the TGA in advertising (including on product labels).
- Closed onConsultationConsultation: Proposed amendments to the Poisons Standard in relation to paracetamol - ACMS meeting, November 2022Closing date: 14 October 2022
- Closed onConsultationConsultation: Detailed considerations for implementing the proposed Australian medical device UDI regulatory frameworkThe TGA is seeking feedback on the third consultation paper published by the TGA relating to the Australian implementation of a Unique Device Identification (UDI) System for medical devices.
- Closed onConsultationConsultation: Proposed amendments to the Poisons Standard – ACCS, ACMS and joint ACCS/ACMS meetings, November 2022Proposed amendments to the Poisons Standard. Closing date: 29 September 2022
- Closed onConsultationConsultation: Product Information as a package insert in boxed injectablesPublic consultation on the Product Information (PI) as a package insert in boxed injectable products.
- Closed onConsultationConsultation on proposed regulatory changes for clinical trials of medical devicesThe (TGA) is seeking feedback on proposed regulatory changes to strengthen safety oversight of clinical trials for medical devices.
Pages
- Current page 1
- Page 2
- Page 3
- Page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- Next page Next ›
- Last page Last »